Calcium pyrophosphate dihydrate gout and other crystal deposition diseases.
The number of crystal or birefringent particles associated with arthritis is increasing, and a uniform taxonomy is needed. The term gout has been proposed as a generic term for these diseases based on historical, clinical, and crystallographic reasons. Calcium pyrophosphate dihydrate gout follows monosodium urate gout in frequency, and its spectrum of clinical manifestations continues to grow. Familial calcium pyrophosphate dihydrate gout was described for the first time in kindreds studied in England and Tunisia; new Jewish and Spanish kindreds were also reported. Type I collagen was shown to nucleate nativelike calcium pyrophosphate dihydrate crystals, and pyrophosphate elaboration was explored in cartilage explants in an attempt to reproduce the in vivo metabolic or endocrine disorders associated with calcium pyrophosphate dihydrate gout. The effect of pyrophosphatase and different cofactors such as magnesium in dissolving calcium pyrophosphate dihydrate crystals was investigated. High-resolution electron microscopy was used to study the interrelation between apatite and other basic calcium phosphate crystals in apatite gout. Raman microscopy was applied for the first time to identify crystals in biologic specimens. A simple and specific technique for basic calcium phosphate crystal identification is necessary to understand the relationship between different calcium phosphate crystals and osteoarthritis. Several reports about children and young patients with primary oxalate gout described the effect of oxalate on eyes, periodontal tissues, and bone. Multicenter studies showed poor results of renal transplantation, but favored combined liver and renal transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
Reginato
A J
AJ
University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Camden.
D002114:Calcinosis / Q000378:metabolism*; D002129:Calcium Oxalate / Q000378:metabolism; D002131:Calcium Pyrophosphate / Q000378:metabolism*; D003460:Crystallization; D017886:Durapatite; D006073:Gout / Q000378:metabolism*; D006801:Humans; D006882:Hydroxyapatites / Q000378:metabolism; D007592:Joint Diseases / Q000378:metabolism*
D006882:Hydroxyapatites; D002129:Calcium Oxalate; D017886:Durapatite; D002131:Calcium Pyrophosphate